GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galera Therapeutics Inc (OTCPK:GRTX) » Definitions » YoY EBITDA Growth

GRTX (Galera Therapeutics) YoY EBITDA Growth : 80.26% (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Galera Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Galera Therapeutics's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was 80.26%.

Galera Therapeutics's EBITDA per Share for the three months ended in Jun. 2024 was $-0.08.

Galera Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Galera Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galera Therapeutics YoY EBITDA Growth Chart

Galera Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial -1,003.45 79.33 -1.44 33.62 43.04

Galera Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.83 40.13 81.39 79.11 80.26

Galera Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Galera Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-1.064--1.868)/ | -1.868 |
=43.04 %

Galera Therapeutics's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (Q: Jun. 2024 )
=(EBITDA per Share (Q: Jun. 2024 )-EBITDA per Share (Q: Jun. 2023 )) / | EBITDA per Share (Q: Jun. 2023 )) |
=(-0.075--0.38)/ | -0.38 |
=80.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galera Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Galera Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Galera Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galera Therapeutics Inc (OTCPK:GRTX) » Definitions » YoY EBITDA Growth
Comparable Companies
TMBR CMRA IMNN ONVO VYNE ARAV EVLO BNTC ENZN EDSA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
P.O. Box 134, Malvern, PA, USA, 19355
Website
https://www.galeratx.com
Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).
Executives
Mel Sorensen director, officer: President and CEO 7 RAPPS RUN DRIVE, MALVERN PA 19355
Mark Bachleda officer: Chief Commercial Officer C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BOULEVARD, #110, MALVERN PA 19355
Chris Degnan officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Eugene P. Kennedy officer: Chief Medical Officer 2503 SOUTH LOOP DRIVE, AMES IA 50010
Linda West director C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Jennifer Evans Stacey officer: See Remarks AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Jon T Holmlund officer: Chief Medical Officer
Lawrence M Alleva director 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Novo Holdings A/s 10 percent owner, other: SEE REMARKS TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joel F. Sussman officer: Chief Accounting Officer C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD. #110, MALVERN PA 19355
Novartis Bioventures Ltd 10 percent owner C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Sofinnova Venture Partners Ix, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Blackstone Clarus Gp L.p. 10 percent owner C/O THE BLACKSTONE GROUP INC., 345 PARK AVENUE, NEW YORK NY 10154
Clarus Iv-a, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142